Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 7/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.48 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.48 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.48 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BAX | Q07812 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535812 | 0.94 | FFAR1 (0.53) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL5539299 | 0.92 | FFAR1 (0.51) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL5541353 | 0.88 | FFAR1 (0.58) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL19322272 | 0.87 | FFAR1 (0.62) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL2201304 | 0.87 | FFAR1 (0.62) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL28656989 | 0.85 | MMP12 (0.46) | FFAR1LTA4HPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL19322285 | 0.85 | FFAR1 (0.60) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL19322269 | 0.85 | FFAR1 (0.60) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL19322273 | 0.85 | FFAR1 (0.60) | FFAR1LTA4HTSHRPLAAT3PLAAT5 | |
| SCHEMBL28665825 | 0.84 | HDAC2 (0.45) | FFAR1LTA4HPLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | KURARAY CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| CN-118255941-A | Photopolymerizable composition for 3D printer comprising polymerizable monomer having allophanate bond | 株式会社松风 | 2024-06-28 | — | — | CN | disclosed |
| US-11981763-B2 | Resin composition for stereolithographic modeling | KURARAY NORITAKE DENTAL INC. (JP) | 2024-05-14 | — | — | US | disclosed |
| CN-114072439-B | Curable composition and resin composition for photofabrication comprising same | 株式会社可乐丽 | 2024-05-14 | — | — | CN | disclosed |
| CN-113993497-B | Curable composition and resin composition for photofabrication comprising same | 株式会社可乐丽 | 2024-03-22 | — | — | CN | disclosed |
| EP-3900693-B1 | USE OF A RESIN COMPOSITION | KURARAY NORITAKE DENTAL INC (JP) | 2024-03-20 | — | — | EP | disclosed |
| CN-112752776-B | Resin composition for photofabrication | 可乐丽则武齿科株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | KURARAY CO., LTD. (JP) | 2023-11-14 | — | — | US | disclosed |
| EP-4268792-A1 | ADHESIVE COMPOSITION FOR PHOTOFABRICATION ARTICLES | Kuraray Noritake Dental Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-113677293-B | Curable composition for dental restoration | 可乐丽则武齿科株式会社 | 2023-10-10 | — | — | CN | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1149214-C | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | ������������ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-6492364-B1 | Triazolo and derivatives as chemokine inhibitors | TORAY INDUSTRIES, INC. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | WASF2, COPE, ARCN1 | FFAR1 493/4885LTA4H 1081/4885TSHR 4743/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | FFAR1 105/4885LTA4H 3452/4885TSHR 319/4885 |
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | ARL1, ASH2L, VCL | FFAR1 1616/4885LTA4H 640/4885TSHR 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.